Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Can We Turn Off The “Covid-Biting-Tail” Inflammation?, Valentina Giudice, Amelia Filippelli, Carmine Selleri
Can We Turn Off The “Covid-Biting-Tail” Inflammation?, Valentina Giudice, Amelia Filippelli, Carmine Selleri
Translational Medicine @ UniSa
To date, SARS-CoV-2 has infected more than 32 million people, and 30% of cases needs intensive care treatment for severe Covid-19 and related acute respiratory distress syndrome (ARDS). Despite medical efforts, mortality rate is still high, and no specific therapies have been outlined yet. Preliminary evidence from case reports and clinical trials using anti-inflammatory and anti-complement drugs shows a deep and overwhelmed inter-play between adaptive and immune responses triggered by SARS-CoV-2 infection. Therefore, a combinatorial therapeutic strategy targeting both inflammation and immune system might more efficiently stop this inflammatory loop and prevent the development of ARDS.
Validation Of A Lysis Buffer Containing 4 M Guanidinium Thiocyanate (Gitc)/ Triton X-100 For Extraction Of Sars-Cov-2 Rna For Covid-19 Testing: Comparison Of Formulated Lysis Buffers Containing 4 To 6 M Gitc, Roche External Lysis Buffer And Qiagen Rtl Lysis Buffer, Martina F. Scallan, Catherine Dempsey, John Mcsharry, Isabelle O'Callaghan, Paula M. O'Connor, Conor P. Horgan, Edel Durack, Paul D. Cotter, Sarah Hudson, Humphrey A. Moynihan, Brigid Lucey
Validation Of A Lysis Buffer Containing 4 M Guanidinium Thiocyanate (Gitc)/ Triton X-100 For Extraction Of Sars-Cov-2 Rna For Covid-19 Testing: Comparison Of Formulated Lysis Buffers Containing 4 To 6 M Gitc, Roche External Lysis Buffer And Qiagen Rtl Lysis Buffer, Martina F. Scallan, Catherine Dempsey, John Mcsharry, Isabelle O'Callaghan, Paula M. O'Connor, Conor P. Horgan, Edel Durack, Paul D. Cotter, Sarah Hudson, Humphrey A. Moynihan, Brigid Lucey
Dept. of Biological Sciences Preprints
The COVID-19 pandemic has resulted in increased need for diagnostic testing using reverse transcriptase real-time PCR (RT-PCR). An exponential increase in demand has resulted in a shortage of numerous reagents in particular those associated with the lysis buffer required to extract the viral RNA. Herein, we describe a rapid collective effort by hospital laboratory scientists, academic researchers and the biopharma industry to generate a validated lysis buffer. We have formulated a 4M Guanidinium thiocyanate (GITC)/ Triton X-100 Lysis buffer which provides comparable results with the recommended reagents. This buffer will ease the burden on hospital labs in their heroic efforts …
Preparing For Shortages Of Future Covid-19 Drugs: A Data-Based Model For Optimal Allocation, Charlie L. Sy, Kathleen Aviso, Christina D. Cayamanda, Anthony F. Chiu, Rochelle Irene Lucas, Michael Angelo Promentilla, Luis F. Razon, Raymond R. Tan, John Frederick Tapia, Ador Torneo, Aristotle T. Ubando, Derrick Ethelbhert C. Yu
Preparing For Shortages Of Future Covid-19 Drugs: A Data-Based Model For Optimal Allocation, Charlie L. Sy, Kathleen Aviso, Christina D. Cayamanda, Anthony F. Chiu, Rochelle Irene Lucas, Michael Angelo Promentilla, Luis F. Razon, Raymond R. Tan, John Frederick Tapia, Ador Torneo, Aristotle T. Ubando, Derrick Ethelbhert C. Yu
Angelo King Institute for Economic and Business Studies (AKI)
Drugs for the treatment of Covid-19 are currently beign tested, and those that are apporved for use are likely to be in short supply due to the global scale of the pandemic. This policy brief proposes a model for optimally allocating future Covid-19 drugs to patients to minimize deaths under conditions of resource scarcity. A linear programming model is developed that estimates the potential number of deaths that may result from Covid-19 under two scenarios: with antivirals and without antivirals. It takes into account patient risk level, the severity of their symptoms, resource availability in hospitals (i.e. hospital beds, critical …